Skip to main content
Download PDF

PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma

Journal of Translational Medicine volume 14, Article number: 137 (2016) Cite this article

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressively malignant tumors with dismal prognosis. Profilin 2 (PFN2) is an actin-binding protein that regulates the dynamics of actin polymerization and plays a key role in cell motility. Recently, PFN2 have emerged as significant regulators of cancer processes. However, the clinical significance and biological function of PFN2 in ESCC remain unclear.

Methods

PFN2 protein expression was validated by immunohistochemistry (IHC) on tissue microarray from Chinese Han and Kazakh populations with ESCC. The associations among PFN2 expression, clinicopathological features, and prognosis of ESCC were analyzed. The effects on cell proliferation, invasion and migration were examined using MTT and Transwell assays. Markers of epithelial–mesenchymal transition (EMT) were detected by Western blot analysis.

Results

Compared with normal esophageal epithelium (NEE), PFN2 protein expression was markedly increased in low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), and ESCC, increased gradually from LGIN to ESCC, and finally reached high grade in HGIN in the Han population. Similarly, PFN2 protein was more overexpressed in ESCC than in NEE in the Kazakh population. The results of Western blot analysis also showed that PFN2 expression was significantly higher in the ESCC tissue than in a matched adjacent non-cancerous tissue. PFN2 expression was positively correlated with invasion depth and lymph node metastasis. High PFN2 expression was significantly correlated with short overall survival (OS) (P = 0.023). Cox regression analysis revealed that PFN2 expression was an independent prognostic factor for poor OS in ESCC. Downregulation of PFN2 inhibited, rather than proliferated, cell invasion and migration, as well as induced an EMT phenotype, including increased expression of epithelial marker E-cadherin, decreased mesenchymal marker Vimentin, Snail, Slug and ZEB1, and morphological changes in ESCC cells in vitro.

Conclusions

Our findings demonstrate that PFN2 has a novel role in promoting ESCC progression and metastasis and portending a poor prognosis, indicating that PFN2 could act as an early biomarker of high-risk population. Targeting PFN2 may offer a promising therapeutic strategy for ESCC treatment.

Background

Esophageal squamous cell carcinoma (ESCC), a prevalent malignant neoplasm, is the sixth leading cause of cancer-related deaths globally [1, 2]. China has the highest incidence and mortality rate for ESCC, the dominant pathological type of esophageal carcinoma (accounting for 90 %) [3, 4]. Despite the improvement in diagnosis and treatment, the survival of patients with advanced stages of ESCC remains bleak because of early lymph node metastasis, with a 10 % 5 year survival rate for patients [5–7]. In sharp contrast, the 5 year survival rate of patient with early stage of ESCC is higher than 90 % [8]. However, most patients with ESCC are diagnosed at the advanced stage at the time of initial diagnosis. Although various biomarkers have been identified over the past few decades, sensitive and specific molecule markers for early detection and exact indicators for ESCC prognosis are not currently available [9, 10]. Therefore, novel biomarkers that can help in early detection, precise prognosis and individualized therapy of ESCC patients are needed.

Profilins are 12–15 kDa actin-binding proteins found in eukaryotes [11]. These proteins sequester actin monomer protein and regulate the dynamics of actin polymerization [12, 13]. In mammals, four discrete profilin genes (PFN1, PFN2, PFN3, and PFN4) have been identified. PFN1, the mainstay of the profilin family, is ubiquitously expressed in all cell types, except skeletal muscle [13, 14]. In amniotes, two alternatively spliced variants of PFN2 (PFN2a and PFN2b) have been identified. PFN2a is a major isoform that is predominantly expressed in neuronal cells. Isoform PFN2b, of which mRNA is detectable in a finite number of adult tissues mainly in the kidney, is rare [15, 16]. PFN3 and PFN4 expressions are limited to the testis [17, 18]. In general, PFN1 and PFN2, as the most common profilins in mammalian cells, display similar actin monomer-binding properties [19]. Profilin accelerates the extension of the uncapped actin filament in the presence of formin and then depolymerizes the capped actin filament, thereby leading to cytoskeletal changes [20, 21]. In addition, the disruption of profilin by gene deletion of PFN1 in null mice [22] or by anti-profilin transfection in bovine oocytes [23], results in early embryonic death. In response to depolarization, those mice lacking PFN2 exhibited a hindered synaptic actin polymerization [24]. These phenomena indicate the non-redundant roles of PFN1 and PFN2 in vertebrate gastrulation.

In recent years, the properties of the profilin family that is involved tumors in progression have been reported. PFN1 has been viewed as a negative regulator for the migration and invasion of breast cancer cells [25–27]. However, a recent report highlighted the opposite roles of PFN1 and PFN2 in the membrane protrusion, cell migration and invasion of breast cancer cells [28]. Another recent report showed that PFN1 had contrasting effects on breast cancer in a context-dependent manner [29]. Other reports suggested that post-translational modifications, such as phosphorylation of PFN1 at Ser 137 or Tyr 129, could change the properties of cancer cells [30–32]. Hence, the roles of profilin in various cancers need to be further clarified. Similarly, the biological function of PFN2 in digestive tract tumors remains controversial. In oral squamous cell carcinoma (OSCC), PFN2 inhibits tumor growth and aggressiveness [33]. Nevertheless, PFN2 significantly enhanced migration and invasion ability of HT29 human colorectal cancer stem cells [34]. However, only few studies have investigated the role of PFN2 in ESCC progression.

In this study, we explored the expression of PFN2 in ESCC and precursor lesions from two different races and then analyzed the associations of PFN2 expression with the clinicopathologic features of ESCC. Functional studies were performed to identify the undiscovered biological function of PFN2 in ESCC cells. In sum, PFN2 assumes a tumor-promoting role in ESCC progression and metastasis by inducing EMT. PFN2 may also function as an independent prognostic biomarker and chemotherapeutic target for ESCC patients from Han and Kazakh ethnic populations, particularly those who are suffering from early stages of cancer.

Methods

Patients and tissue specimens

The ESCC tissues used for IHC staining of PFN2 were gathered from two separate groups of ESCC. One group comprised 192 Han Chinese patients with ESCC collected between 1997 and 2013 from the First University Hospital, Shihezi University School of Medicine. The other group included 168 Kazakh ESCC patients whose data were gathered between 1984 and 2011 from Xinjiang Yili Prefecture Friendship Hospital, People’s Hospital of Xinjiang Uyghur Autonomous Region, and the First University Hospital, Shihezi University School of Medicine. No restrictions regarding sex, age, or stage of disease were placed. Except for diagnostic biopsies, iatrochemistry, or radiotherapy, none of the patients received prior surgery. Data on clinicopathologic parameters, such as invasion depth and lymph node metastasis, were collected. Tumor node metastasis (TNM) stages were assessed for each case in accordance with the seventh edition of the AJCC cancer-staging manual [35]. All patients involved in the study gave their written informed consent, and the research protocol used in this study was approved by the medical ethics and human clinical trial committee of the Shihezi University School of Medicine.

The clinical characteristics of patients from both validation centers are listed in Table 1. Immediately after surgery, 192 cancerous tissues, together with their 135 adjacent mucosa, were collected from the Han patient group. A total of 168 cancerous tissues, with their 55 adjacent mucosa, were collected from the Kazakh patient group. The tissues were fixed in 10 % formalin for 24 h and then embedded in paraffin. Moreover, from the Han group samples, 85 precursor lesions, called esophageal squamous intraepithelial neoplasia (ESIN), were selected, including 52 LGIN and 33 HGIN. The diagnoses of all the subjects were from two pathologists independently. Clinical and pathological information of all cases were acquired from medical records. Follow-ups were conducted on 71 Han patients by phone or other methods, with a follow-up deadline of 10 July 2015.

Table 1 PFN2 clinicopathological characteristics of patients with ESCC from Chinese Han and Kazakh population
Full size table

Tissue microarray fabrication and immunohistochemistry analysis

Tissue microarray (TMA) construction and IHC process were implemented according to previous research [36]. In brief, paraffin-embedded samples was first cut into 4-μm-thick slices and stained using hematoxylin and eosin (HE). Many cancerous regions of each sample were distinguished from HE-stained slides. Subsequently, the aforementioned areas were located to the ready paraffin block for TMA fabrication. Then, we bore a hole in these regions and inserted into a recipient paraffin block using a tissue arrayer with a hollow needle with a diameter of 1.0 mm (ALPHELYS, Plaisir, France). Finally, serial slices were built from the TMA blocks for IHC staining.

PFN2 protein expression was detected using the Envision system (Dako, Carpinteria, CA). Next, the tissue slices were prepared on microslides and baked at 65 °C for 2 h and deparaffinized using xylene and rehydrated using alcohol. Then, the slices were immersed in hydrogen peroxide (3 %) for 10 min to eliminate endogenous peroxidase. Subsequently, antigen retrieval was implemented by heating the tissue slices in a pressure cooker under high power for 10 min in a citrate buffer solution. The tissue sections were then incubated with anti-PFN2 antibody (ab55611; Abcam, Cambridge, MA; dilution 1: 400) at 4 °C overnight. By contrast, negative control sections were incubated with PBS. The next day, the slides were incubated with a second antibody for 30 min at 37 °C. Afterward, these slices were covered with a fresh diaminobenzidine solution then stained with hematoxylin and dehydrated with graded alcohol and xylene. Finally, neutral balsam (ZSGB-Bio, Beijing, China) and coverslips were added, and the slices were air dried before the analysis.

Semi-quantitative assessment and scoring

With respect to the assessment of IHC results, we referred to a previous scoring method [37]. The expression of PFN2 was semi-quantitatively scored on the basis of the percentage of positive cells and cytoplasmic/nuclear staining intensity. The percentage of positive cells were 0 (<5 % positive cells), 1 (6–25 % positive cells), 2 (26–50 % positive cells), 3 (51–75 % positive cells), or 4 (>75 % positive cells). The cytoplasmic/nuclear staining intensity was classified into the following: 0 score (negative), 1 (light yellow), 2 (yellow), and 3 (brown). The percentage of positive cells and staining intensity were then multiplied to obtain the IHC score (IS) for each patient. All immunostained results were assessed by two pathologists independently and finally assigned a consistent score. If the two pathologists disagreed over the immunohistochemical results, a third pathologist was invited to assist in analyzing the results. Thus, the IS ranged from 0 to 12 scores. The optimal cut-off values for the evaluation system can be perceived as follows: high expression of PFN2 was defined as an expression index score of ≥4, and low expression of PFN2 was defined as an expression index score of <4. These cases were divided into two groups based on their IS of PFN2 staining. Cases with scores of ≥4 were categorized as the high expression group, and cases with a score of <4 were categorized as the low expression group.

Cell culture and cell transfection

Three EC cell lines (EC9706, Eca109, TE-1) were obtained from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences. Cell culture was performed in DMEM Medium (GIBCO-BRL) in addition with 10 % fetal calf serum, 100 mg/mL streptomycin, and 100 U/mL penicillin in moist air containing 5 % CO2 at 37 °C. Oligonucleotide small interfering RNA (siRNA) duplexes were synthesized by GenePharma (Shanghai, China). The following siRNA sequence for PFN2 was used: 5′-CAU AUG AAC UCG CUU UAU A-3′. A non-target scrambled siRNA was used as the negative control: 5′-UUC UCC GAA CGU GUC ACG UTT-A-3′. The cells were transfected with 130 nM siRNA targeting PFN2 or RNAi negative control duplexes using HiPerFect transfection reagents (Qiagen, Hilden, Germany) in serum-free conditions according to the Quick-Start Protocol.

Western blot analysis

Western blot analyses were performed on cell lysate prepared from three esophageal cancer cell lines and esophageal tissue as described previously. Equal amount of protein lysate were loaded and separated on 10 % SDS–polyacrylamide gel electrophoresis and then transferred to a PVDF membrane (Millipore, USA). After being blocked by 5 % fat-free milk in TBS buffer, membranes were probed with the following antibodies overnight at 4 °C: mouse monoclonal anti-PFN2 (Abcam; 1:1000 dilution), rabbit anti-E-cadherin (Santa Cruz; 1:200 dilution), rabbit anti-Vimentin (Abcam; 1:1000 dilution), rabbit anti-Snail (Proteintech; 1:500 dilution), rabbit anti-Slug (Proteintech; 1:200 dilution), rabbit anti-ZEB1 (Proteintech; 1:500 dilution) and mouse anti-β-actin (Zhongshan Biotechnology; 1:1000). Bound antibodies were detected with secondary HRP-conjugated antibodies (Santa Cruz) for 2 h at room temperature. After washing, the resulting bands were visualized using the standard ECL procedure (Kangwei, Beijing). Images were acquired using the image acquisition system (BioRad, USA) and their grayscale value was analyzed by the image analysis program (Gel-Pro Analyzer 4.0, USA).

Measurement of cell proliferation

Cells (4 × 103 cells/well) were seeded at 96-well plates in triplicate. The cells were incubated for 24, 48, and 72 h, and were then stained with 20 μL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye (5 mg/mL, Solarbio) for 4 h. Subsequently, supernatants were removed, and 150 μL of DMSO was added to each well. The plates were shook rapidly until the formazan crystals dissolved completely. The absorbance value of each well was detected at 490 nm using a spectrophotometer (Bio-Rad, USA). Independent experiments were repeated three times.

Cell migration and invasion assays

Cell migration and invasion assays were performed as previously described [37]. Migration assay was performed by using Transwell insert chambers (Corning, USA). Transfected cells measuring 8 × 104 were plated onto the top surface of the chamber in triplicate. After incubation for 24 h under suitable conditions, non-invaded cells were removed, and the membranes containing the invaded cells were fixed and stained with 0.1 % crystal violet. More than six fields were counted for each sample. Three independent experiments were performed. For the cell invasion assay, the process was analogous to the cell migration assay, except for that the membranes were smeared with Matrigel (BD Biosciences, USA) and the seeded cells were incubated for 8 h.

Statistical analysis

Statistical analysis of the experimental data was performed using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA). Categorical data were compared using χ2 test and Fisher’s exact test to analyze the differences in PFN2 expression and clinical characteristics. The sensitivity and specificity of ESCC and precancerosis forecast were assessed by receiver operating characteristic (ROC) curves. Survival curves were analyzed using the Kaplan–Meier method. A Cox regression model was used to analyze the independent prognostic factors. All statistical results were demonstrated using GraphPad Prism 5 software. For all tests, the P values of less than 0.05 were considered statistically significant.

Results

PFN2 is overexpressed in ESIN and ESCC tissue compared with NEE tissue

To determine the clinical relevance of PFN2 and explore its potential role in ESCC progression, we detected the expression of PFN2 protein by IHC staining in NEE, LGIN, HGIN, and ESCC tissues gathered from the Chinese Han and Kazakh populations. The IHC results revealed that PFN2 staining was mainly located in the nuclei/cytoplasm, and the distribution of PFN2 staining was significantly different during the different development phases of ESCC. For the Han population, the IHC analysis displayed that the frequency of PFN2 protein overexpression was lowest in the NEE tissue (8.1 %), but its frequency increased gradually along with the progress of esophageal cancer, with 40.4 % (21/52) of LGIN and 91.0 % (30/33) of HGIN. Meanwhile, a slight decrease in frequency was observed at 82.8 % (159/192) of ESCC, but a high expression level of PFN2 protein was still observed. In NEE, PFN2 staining was weak or negative and was predominantly observed in the nuclei/cytoplasm of basal cells (Fig. 1a); however, PFN2 was expressed in HGIN and ESCC cells with the strongest signal in nuclei/cytoplasm (Fig. 1b, c). The tendency of PFN2 overexpression rates exhibited a progressive increase in NEE, LGIN, and ESCC, and peaked in HGIN (Fig. 1d). Moreover, the four-level score (0–1, 2–3, 4–8, and 9–12) distribution of PFN2 protein expression in the different development stage of ESCC was significantly distinct (Fig. 1e). An in-depth analysis uncovered that the overexpression rates of PFN2 protein increased significantly in LGIN, HGIN, and ESCC compared with that in NEE (P < 0.001). Meanwhile, significant differences were observed between LGIN and HGIN (P < 0.001), as well as between LGIN and ESCC (P < 0.001). PFN2 overexpression was highest in HGIN, not ESCC. However, the difference between these two subgroups was not statistically significant (P > 0.05, Table 2). The expression of PFN2 protein was also analyzed in the Kazakh patients. The statistical analysis showed that the staining density of PFN2 in ESCC tissue was distinctly stronger than that in adjacent normal tissue in the Kazakh population (P < 0.001, Fig. 2a, b, c). High PFN2 expression was detected in 146/168 (86.9 %) of ESCC tissues and only in 8/55 (14.5 %) of normal samples. The results were constant the findings from the Han patients, which indicated no differences with regard to the profile of PFN2 expression between different histologic types gathered from the Chinese Han and Kazakh groups (Table 3).

Fig. 1
figure 1

IHC analysis of PFN2 protein in adjacent normal tissues, precancerous lesions, and ESCC tissues from Chinese Han population. Typical PFN2 immunostaining in a NEE, b LGIN and HGIN, and c ESCC in the Chinese Han population (top image magnification ×40; middle and bottom image magnification ×200; bottom image stands for negative control) PFN2 staining was located to the nuclei/cytoplasm. d (Box plot) Range of PFN2 immunoreactivity score in NEE, LGIN, HGIN, and ESCC tissues (**P < 0.01, ***P < 0.001). e (Bar chart) Distribution ratio of NEE, LGIN, HGIN and ESCC tissues in four-level score (0–1, 2–3, 4–8, and 9–12) of PFN2 expression

Full size image
Table 2 PFN2 protein expression during cancer progression by IHC analysis in Han population
Full size table
Fig. 2
figure 2

IHC analysis of PFN2 protein in adjacent normal tissues and ESCC tissues from Kazakh population. Typical PFN2 immunostaining in a NEE and b ESCC in the Chinese Kazakh population (top image magnification ×40; middle and bottom image magnification ×200; bottom image stands for negative control). PFN2 staining was localized to the nuclei/cytoplasm. c (Box plot) Range of PFN2 expression score in NEE and ESCC tissues (***P < 0.001). d PFN2 expression at the protein level was detected by Western blot analysis in 11 matched pairs of ESCC tissues (T) and adjacent normal tissues (N). β-actin was used as an endogenous control. e Bar chart showing the relative PFN2 protein expression level to β-actin in ESCC tissues and paired NEE tissues (**P < 0.01)

Full size image
Table 3 Relationship of PFN2 expression between Kazakh and Han ESCC tissues
Full size table

Furthermore, we examined the expression of PFN2 in 11 matched pairs of ESCC and adjacent normal tissue by Western blot. As shown in Fig. 2d, e, in all cases, PFN2 expression in the ESCC tissue was visibly higher than in adjacent normal tissue from the same ESCC patient (P < 0.01), which was consistent with the findings in IHC with respect to the PFN2 expression.

PFN2 expression is associated with lymph node metastasis and invasion depth in ESCC

To ascertain whether the protein expression levels of PFN2 were indicative of the development state of ESCC, we further investigated the relationship between PFN2 expression and clinicopathological characteristics in two independent groups of patients with ESCC. As summarized in Table 4, in Han patients, a high PFN2 expression more frequently occurred in ESCC tissue with deep invasion (P = 0.004), and a positive lymph node metastasis occurred in Kazakh patients (P = 0.010). However, no significant correlation between PFN2 expression and other clinicopathological variables, such as gender, age, differentiation, and TNM stage, were found among the Chinese Han and Kazakh groups.

Table 4 Correlation between PFN2 expression and clinicopathologic features in ESCC from Han and Kazakh population
Full size table

Upregulated PFN2 expression predicts unfavorable prognosis in ESCC patients

To assess the value of PFN2 for the prognosis of postsurgical ESCC patients, the relationship between PFN2 expression and OS of ESCC was analyzed using Kaplan–Meier method. The median survival time for patients with high PFN2 expression was 12 months (range, 1–96 months) and 42 months (range, 1–96 months) for patients with low PFN2 expression, which indicated that ESCC patients with high PFN2 expression had significantly shorter OS rates and greater risk of death than those with low PFN2 expression (log-rank test, χ2 = 5.203, P = 0.023) (Fig. 3a, b).

Fig. 3
figure 3

Kaplan–Meier survival curves for patients with high PFN2 expression and those with low expression. a ESCC patients with high PFN2 expression (IS ≥ 4) experienced a significantly shorter survival period after surgery than those with low PFN2 expression (IS < 4) (P < 0.05). b Patients with high PFN2 expression had a greater risk of death than those with low PFN2 expression (P < 0.05)

Full size image

In addition, Cox proportional hazards modes were utilized to identify independent prognostic factors for ESCC survival. A univariate Cox analysis revealed that PFN2 protein level (HR = 2.669, 95 % CI = 1.147–6.209, P = 0.023), together with invasion depth (HR = 3.085, 95 % CI = 1.079–8.819, P = 0.036) and TNM stage (HR = 2.981, 95 % CI = 1.380–6.437, P = 0.005), was responsible for OS of ESCC patients (Table 5). Furthermore, in a multivariate analysis of significant factors, only PFN2 protein level (HR = 2.465, 95 % CI = 1.020–5.955, P = 0.045) and TNM stage (HR = 3.037, 95 % CI = 1.094–8.833, P = 0.033) were independently associated with OS of ESCC (Table 5). Overall, the data indicated that the PFN2 overexpression independently predicted a worse prognosis for ESCC patients.

Table 5 Univariate and multivariate Cox regression analyses of the prognostic variables in ESCC patients
Full size table

PFN2 may be a feasible diagnostic bioindicator for ESCC and ESIN

Using the adjacent normal mucosa as control, the ROC curves for distinct types of tissue elucidated the point on the curve closest to (0.0, 1.0), which maximizes both sensitivity and specificity for ESCC, HGIN, and LGIN. Using the IHC cut-off scores of PFN2 as a proposed standard, the ESCC, HGIN, and LGIN tissue were distinguished easily from the control. In the Chinese Han populations, in terms of cut-off score of 4, the sensitivity and specificity values for ESCC were 96.6 and 63.0 %. HGIN and LGIN were analyzed to obtain sensitivity and specificity values of 97.0 and 63.0 %, as well as 67.3 and 63.0 %, respectively. In the Kazakh group, the sensitivity and specificity values for ESCC were 90.1 and 57.3 %, respectively (cut-off score of 4) (Fig. 4, Additional file 1: Table S1). These findings support the conjecture that PFN2 may be a feasible diagnostic bioindicator for ESCC and ESIN.

Fig. 4
figure 4

ROC curve analysis of the PFN2 IHC scores for detecting precancerous lesions and ESCC tissues. a ESCC tissues, b HGIN tissues, and c LGIN tissues of the Chinese Han population and d ESCC tissues of the Kazakh population from the controls. The area under the curve (AUC) is 0.893, 0.947, 0.743, and 0.860, respectively

Full size image

PFN2 induces EMT phenotype and promotes the migration and invasion of ESCC cell lines

EMT contributes to tumor invasion and metastasis in various cancers; therefore, we evaluated whether essential EMT-related markers were altered in our model. From the results of Western blot, we observed an efficient knockdown of PFN2, with over 50 % decrease in protein level in the PFN2-siRNA transfected ESCC cells, and the upregulated epithelial marker E-cadherin and significantly decreased mesenchymal markers: Vimentin, Snail, Slug and ZEB1 in Eca109, EC9706, and TE-1 cells with knockdown of PFN2 compared with the control groups (Fig. 5a, b, c, d). The Western blot results suggested that PFN2 could regulate the molecular changes of EMT in ESCC cells.

Fig. 5
figure 5

Change in EMT phenotype and morphology after PFN2-siRNA transfection in ESCC cells. a After silencing of PFN2 with PFN2-siRNA in ESCC cells, the protein levels of E-cadherin, Vimentin, Snail, Slug and ZEB1 were measured by Western blot. (Bar chart showing) Relative protein levels of E-cadherin, Vimentin, Snail, Slug and ZEB1 normalized to β-actin in b ECa109 cells, c EC9706 cells and d TE-1 cells. e Morphological change images of ECa109 cells after transfecting with PFN2-siRNA for 24, 36, and 48 h

Full size image

Our data on clinical samples showed that PFN2 expression is positively associated with invasion depth and lymph node metastasis of ESCC patients. Hence, we wanted to determine whether PFN2 is essential for ESCC cell migration and invasion in vitro. After silencing of PFN2, Eca109 cells exhibited a morphological change from an elongated fibroblastic phenotype to an epithelial cobblestone phenotype, which indicated that EMT weakens (Fig. 5e). Subsequently, Transwell assays showed that depletion of PFN2 significantly suppressed the migration and invasion of Eca109 and EC9706 cell lines. As shown in Fig. 6a, b, the number of cells that traversed the membrane was significantly decreased in PFN2-siRNA-treated groups compared with that in the control groups (P < 0.01). Similarly, the number of cells that invaded the Matrigel membrane was also significantly decreased in PFN2-siRNA-treated groups compared with that in the control groups (P < 0.01) (Fig. 6c, d). These results were consistent with the statistical results of clinical specimens, indicating that PFN2 is essential for the migrant and invasive properties of ESCC cells. Taken together, PFN2 may promote the migration and invasion of ESCC cell lines by inducing EMT phenotype.

Fig. 6
figure 6

Alteration of migratory, invasive, and proliferative abilities for ESCC cells after PFN2-siRNA transfection. a Representative images and c display of migration and invasion of ECa109 and EC9706 cells transfected with PFN2-siRNA or siRNA-Control and the quantitative analysis are shown in b and d, respectively. b (Bar chart) and d (data) Mean ± SD of three biological replicates (**P < 0.01, ***P < 0.001). The quantitative analysis of proliferative capability of ECa109, EC9706, and TE-1 cells transfected with PFN2-siRNA or siRNA-Control is exhibited in e, f, g. Plots are represented as mean ± SD of data from three independent experiments

Full size image

Discussion

Accumulating evidence suggests that PFN2 may be linked with multiple cancers. However, the roles of PFN2 in the reported tumors were inconsistent. In OSCC, PFN2 serves as a negative regulator of tumor growth and aggressiveness [33], whereas PFN2 significantly increases migration and invasion ability of lung cancer and colorectal cancer stem cells [19, 34]. However, whether PFN2 serves a similar role in the progression of ESCC is currently unknown. For the first time, we found that the PFN2 expression in the ESCC tissues from Chinese and Kazakh ESCC patients both increased similar to that in their ESIN tissues. Moreover, in vitro assays revealed the biological role of PFN2 in facilitating the migration and invasion of cancer cells by regulating the EMT phenotype of ESCC, thereby proving that PFN2 might be a potential biomarker for the diagnosis and a therapeutic target for the treatment of ESCC.

As a highly aggressive tumor, ESCC involves a multi-stage process, in which NEE follows a series of histological and genetic progression, goes through noninvasive precursor lesions, and finally becomes an invasive cancer [38]. Many reports indicate that precursor lesions have prognostic significance for ESCC because dysplastic lesions are frequently encountered in ESCC tissues [39]. Therefore, the expression of proteins in precursor lesions is usually predictive of ESCC progression. We found that the overexpression of PFN2 was positively related with the progression of ESCC. In Han patients, we observed that the PFN2 protein expression progressively increased from NEE to LGIN, to ESCC, peaking in HGIN, which indicated that PFN2 would soon increase once the esophageal squamous epithelium transformed into ESCC malignant progression. Patients with mild, moderate and severe dysplasia as well as in situ carcinoma have an increased risk of developing aggressive ESCC [40]. Similarly, the PFN2 protein expression was significantly higher in Kazakh ESCC than in NEE. Although the two groups had different ethnic customs and dietary histories, high level of PFN2 protein was equally observed in both Han and Kazakh ESCC tissues. Therefore, we confirmed the notion that PFN2 might function as an oncogene of ESCC. As far as we concerned, this is the first report that exhibits high level of PFN2 protein inamongst ESCC patients from Chinese Han and Kazakh populations. A similar phenomenon was observed in ESIN tissues.

To investigate the feasibility of using PFN2 as a clinical diagnostic biomarker of ESCC and ESIN, we constructed ROC curves to assess the specificity and sensitivity of PFN2 in different types of tissues. We acquired high sensitivity and specificity values that underscored the potential availability of PFN2 as a novel diagnostic biomarker. Notably, our initial data were only derived from immunohistochemical results, which constituted a sensitive and cost-efficient method for estimating protein expression [41]. This method has also been used to recognize several potential diagnostic markers and therapeutic targets [42]. Therefore, other protein analytical methods should be used to further confirm the immunohistochemistry-based results that are presented in this paper. In addition, we found that PFN2 expression influenced the survival of ESCC patients, with overexpression of PFN2 being associated with worse OS. Cox regression analysis revealed that the PFN2 expression could serve as an independent prognostic factor for ESCC. The relations between PFN2 expression and worse OS have been previously analyzed in several tumors. Previous studies also proposed that abnormal PFN2 expression could predict poor prognosis [19, 33]. Our results support the theory that abnormal PFN2 expression may serve as a prognostic biomarker, which in turn highlights the implication that an increased PFN2 expression can be an early indicator of high-risk population and prognostic biomarker.

Another important finding in this study was found that PFN2 expression was positively associated with invasion depth amongst Han patients with ESCC, as well as lymph node metastasis amongst Kazakh ESCC patients. Therefore, PFN2 overexpression may be important for the development of ESCC and can promote the metastasis and aggressiveness of ESCC. Nevertheless, the inconsistent conclusions from these two groups might be attributed to the restrictions in the sample size, the heterogeneity of the population and their different hereditary backgrounds. Therefore, these findings should be explored further in future studies by using uniform ethnic cohorts and employing a larger sample size. Our findings are compatible with those of several reports on PFN2 in other types of tumors. For instance, one research showed that PFN2 mRNA levels and protein were significantly up-regulated in lung cancer tissues, whilst PFN2 overexpression strongly promoted lung cancer migration and invasion [19]. Another study reported that up-regulated PFN2 expression in colorectal cancer stem cells enhanced the ability of migration and invasion [34, 43]. By contrast, Ma et al. observed a decreased PFN2 protein expression in OSCC tissues and suggested that the down-expression of PFN2 in OSCC tissues was significantly associated with vascular invasion and advanced TNM stage [ 33]. These contradictory results might be attributed to the heterogeneity of the tumor and the limited sample size. Moreover, PFN2 molecules could bind tightly with a proline-rich motif, and various proteins contain one or more proline-rich motifs, such as Ena/VASP proteins (Mena, VASP and EVL) [44–46], Arp2/3 complex [47] and WASP [48]. Therefore, PFN2 may be involved in the regulation of different signaling pathways, such as PI3K–AKT [49] and TGF-β/Smad signaling [19], thereby leading to different biological consequences. Therefore, further research must elucidate the association of PFN2 expression with the invasion and metastasis of ESCC by employing a larger sample.

In epithelial cancers, EMT is regarded as one of the major molecular mechanisms that promote invasion and metastasis [50, 51]. Loss of E-cadherin is a fundamental step of EMT by which polarized epithelial cells lose the tight cell–cell junction and enhance the migratory capacity. In our study, E-cadherin was clearly up-regulated by the knockdown of PFN2. This result was in agreement with the decreased migration and invasion abilities of ESCC cells. Some reports showed that several EMT-inducing transcription factors, such as Snail, Slug and ZEB1, could directly or indirectly repress E-cadherin to promote invasion and metastasis [52, 53]. Snail and Slug could bind to the E-box hexa-nucleotide DNA motif in the human E-cadherin promoter by a resembling structure with a highly conserved carboxy-terminal domain [54]. ZEB1 induces EMT by down-regulating E-cadherin and up-regulating a range of mesenchymal markers, such as N-cadherin, Vimentin and MMPs, thereby promoting cell migration, invasion and metastasis [55]. In our study, silencing PFN2 significantly suppressed the expressions of Snail, Slug and ZEB1. These results were consistent with those of previous lung cancer studies [19]. In lung cancer, PFN2 has been identified as a critical activator of TGF-β/Smad signal-inducing EMT. Similarly, another mesenchymal marker, Vimentin, was obviously downregulated by the knockdown of PFN2. Vimentin is a filament that is highly expressed in mesenchymal cells and is generally used to determine those tumor cells that are undergoing EMT based on the positive association of Vimentin expression with the invasion and metastasis in multiple cancers [56]. Notably, our results were accorded with previous ESCC studies [57]. Pang et al. were the first to report that the TGF-β1/Smad signaling pathway could induce EMT in ESCC. Unsurprisingly, the silencing of PFN2 significantly reversed the fibroblastoid-like phenotype of ESCC cells. In other words, the depletion of PFN2 suppressed the invasion and metastasis of ESCC cell lines as well as induced the reversion of EMT, which suggested that PFN2 enhanced the invasion and metastasis of ESCC cell lines by inducing EMT. We contend that PFN2 may promote invasion and metastasis by activating the TGF-β1/Smad signaling pathway inducing EMT in ESCC, but this contention must be clarified further.

However, it must be pointed out that, in the present study, we adopted an approach similar to that of Valenzuela–Iglesias et al. [58]. Specifically, we detected the PFN2 expression as a whole and did not further distinguish the isoforms of PFN2. Therefore, the differences between PFN2a and PFN2b in terms of ESCC progression should be clarified in future studies.

Conclusions

In summary, our clinical study has characterized PFN2 as a molecular marker for ESCC progression and metastasis, and more importantly, our study has identified an independent prognostic factor for ESCC patients, indicating that PFN2 could serve as an early detector of ESCC high-risk population and a novel prognostic marker for ESCC. Moreover, we found knockdown of PFN2 significantly reduced migration and invasion by mediating EMT phenotype in vitro. Targeting PFN2 may offer a promising therapeutic strategy for ESCC treatment.

Abbreviations

ESCC:

esophageal squamous cell carcinoma

PFN2:

profilin 2

IHC:

immunohistochemistry

EMT:

epithelial–mesenchymal transition

NEE:

normal esophageal epithelium

LGIN:

low-grade intraepithelial neoplasia

HGIN:

high-grade intraepithelial neoplasia

ESIN:

esophageal squamous intraepithelial neoplasia

OS:

overall survival

OSCC:

oral squamous cell carcinoma

TNM:

tumor node metastasis

TMA:

tissue microarray

HE:

hematoxylin and eosin

IS:

immunohistochemistry score

ROC:

receiver operating characteristic

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Cui XB, Chen YZ, Pang XL, Liu W, Hu JM, Li SG, et al. Multiple polymorphisms within the PLCE1 are associated with esophageal cancer via promoting the gene expression in a Chinese Kazakh population. Gene. 2013;530:315–22.

    Article  CAS  PubMed  Google Scholar 

  3. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.

    Article  PubMed  Google Scholar 

  4. Wang J, Jia Y, Wang N, Zhang X, Tan B, Zhang G, et al. The clinical significance of tumor-infiltrating neutrophils and neutrophil-to-CD8 + lymphocyte ratio in patients with resectable esophageal squamous cell carcinoma. J Transl Med. 2014;12:7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5.

    Article  CAS  PubMed  Google Scholar 

  6. Liao Y, Xue Y, Zhang L, Feng X, Liu W, Zhang G. Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients. J Transl Med. 2015;13:338.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chen Y-Z, Cui X-B, Hu J-M, Zhang WJ, Li S-G, Yang L, et al. Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness. Apmis. 2013;121:908–18.

    Article  CAS  PubMed  Google Scholar 

  8. Liu J, Xie X, Zhou C, Peng S, Rao D, Fu J. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 2012;41:e7–11.

    Article  PubMed  Google Scholar 

  9. Li H, Zheng D, Zhang B, Liu L, Ou J, Chen W, et al. Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell carcinoma. J Transl Med. 2014;12:196.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang L, Ye SB, Ma G, Tang XF, Chen SP, He J, et al. The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 2013;11:60.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ding Z, Bae YH, Roy P. Molecular insights on context-specific role of profilin-1 in cell migration. Cell Adhes Migr. 2012;6:442–9.

    Article  Google Scholar 

  12. Jockusch BM, Murk K, Rothkegel M. The profile of profilins. Rev Physiol Biochem Pharmacol. 2007;159:131–49.

    CAS  PubMed  Google Scholar 

  13. Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 2004;14:461–9.

    Article  CAS  PubMed  Google Scholar 

  14. Bubb MR, Yarmola EG, Gibson BG, Southwick FS. Depolymerization of actin filaments by profilin. Effects of profilin on capping protein function. J Biol Chem. 2003;278:24629–35.

    Article  CAS  PubMed  Google Scholar 

  15. Di Nardo A, Gareus R, Kwiatkowski D, Witke W. Alternative splicing of the mouse profilin II gene generates functionally different profilin isoforms. J Cell Sci. 2000;113(Pt 21):3795–803.

    PubMed  Google Scholar 

  16. Lambrechts A, Braun A, Jonckheere V, Aszodi A, Lanier LM, Robbens J, et al. Profilin II is alternatively spliced, resulting in profilin isoforms that are differentially expressed and have distinct biochemical properties. Mol Cell Biol. 2000;20:8209–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Braun A, Aszodi A, Hellebrand H, Berna A, Fassler R, Brandau O. Genomic organization of profilin-III and evidence for a transcript expressed exclusively in testis. Gene. 2002;283:219–25.

    Article  CAS  PubMed  Google Scholar 

  18. Obermann H, Raabe I, Balvers M, Brunswig B, Schulze W, Kirchhoff C. Novel testis-expressed profilin IV associated with acrosome biogenesis and spermatid elongation. Mol Hum Reprod. 2005;11:53–64.

    Article  CAS  PubMed  Google Scholar 

  19. Tang YN, Ding WQ, Guo XJ, Yuan XW, Wang DM, Song JG. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun. 2015;6:8230.

    Article  PubMed  Google Scholar 

  20. Yarmola EG, Bubb MR. How depolymerization can promote polymerization: the case of actin and profilin. BioEssays. 2009;31:1150–60.

    Article  CAS  PubMed  Google Scholar 

  21. Lambrechts A, Van Troys M, Ampe C. The actin cytoskeleton in normal and pathological cell motility. Int J Biochem Cell Biol. 2004;36:1890–909.

    Article  CAS  PubMed  Google Scholar 

  22. Witke W, Sutherland JD, Sharpe A, Arai M, Kwiatkowski DJ. Profilin I is essential for cell survival and cell division in early mouse development. Proc Natl Acad Sci USA. 2001;98:3832–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Rawe VY, Payne C, Schatten G. Profilin and actin-related proteins regulate microfilament dynamics during early mammalian embryogenesis. Hum Reprod. 2006;21:1143–53.

    Article  CAS  PubMed  Google Scholar 

  24. Boyl PP, Nardo AD, Mulle C, Sassoe-Pognetto M, Panzanelli P, Mele A, et al. Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-seeking behavior. EMBO J. 2007;26:2991–3002.

    Article  Google Scholar 

  25. Janke J, Schluter K, Jandrig B, Theile M, Kolble K, Arnold W, et al. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med. 2000;191:1675–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, Das T, et al. Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer. 2007;97:1361–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bae YH, Ding Z, Das T, Wells A, Gertler F, Roy P. Profilin1 regulates PI(3,4)P2 and lamellipodin accumulation at the leading edge thus influencing motility of MDA-MB-231 cells. Proc Natl Acad Sci USA. 2010;107:21547–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mouneimne G, Hansen SD, Selfors LM, Petrak L, Hickey MM, Gallegos LL, et al. Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell. 2012;22:615–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ding Z, Joy M, Bhargava R, Gunsaulus M, Lakshman N, Miron-Mendoza M, et al. Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene. 2014;33:2065–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fan Y, Potdar AA, Gong Y, Eswarappa SM, Donnola S, Lathia JD, et al. Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1alpha accumulation. Nat Cell Biol. 2014;16:445–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rizwani W, Fasim A, Sharma D, Reddy DJ, Bin Omar NA, Singh SS. S137 phosphorylation of profilin 1 is an important signaling event in breast cancer progression. PLoS One. 2014;9:e103868.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Diamond MI, Cai S, Boudreau A, Carey CJ Jr, Lyle N, Pappu RV, et al. Subcellular localization and Ser-137 phosphorylation regulate tumor-suppressive activity of profilin-1. J Biol Chem. 2015;290:9075–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ma CY, Zhang CP, Zhong LP, Pan HY, Chen WT, Wang LZ, et al. Decreased expression of profilin 2 in oral squamous cell carcinoma and its clinicopathological implications. Oncol Rep. 2011;26:813–23.

    CAS  PubMed  Google Scholar 

  34. Kim MJ, Lee YS, Han GY, Lee HN, Ahn C, Kim CW. Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells. Biosci Biotechnol Biochem. 2015;79(9):1–9.

    Google Scholar 

  35. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.

    Article  PubMed  Google Scholar 

  36. Li M, Cui X, Shen Y, Dong H, Liang W, Chen Y, et al. ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma. Hum Pathol. 2015;46:707–15.

    Article  CAS  PubMed  Google Scholar 

  37. Cui XB, Shen YY, Jin TT, Li S, Li TT, Zhang SM, et al. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma. J Transl Med. 2015;13:321.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Shimizu M, Nagata K, Yamaguchi H, Kita H. Squamous intraepithelial neoplasia of the esophagus: past, present, and future. J Gastroenterol. 2009;44:103–12.

    Article  PubMed  Google Scholar 

  39. Morita M, Kuwano H, Yasuda M, Watanabe M, Ohno S, Saito T, et al. The multicentric occurrence of squamous epithelial dysplasia and squamous cell carcinoma in the esophagus. Cancer. 1994;74:2889–95.

    Article  CAS  PubMed  Google Scholar 

  40. Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–92.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol. 1998;153:875–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517–25.

    Article  CAS  PubMed  Google Scholar 

  43. Lee HN, Park SH, Lee EK, Bernardo R, Kim CW. Proteomic profiling of tumor-initiating cells in HT-29 human colorectal cancer cells. Biochem Biophys Res Commun. 2012;427:171–7.

    Article  CAS  PubMed  Google Scholar 

  44. Ferron F, Rebowski G, Lee SH, Dominguez R. Structural basis for the recruitment of profilin-actin complexes during filament elongation by Ena/VASP. EMBO J. 2007;26:4597–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lambrechts A, Kwiatkowski AV, Lanier LM, Bear JE, Vandekerckhove J, Ampe C, et al. cAMP-dependent protein kinase phosphorylation of EVL, a Mena/VASP relative, regulates its interaction with actin and SH3 domains. J Biol Chem. 2000;275:36143–51.

    Article  CAS  PubMed  Google Scholar 

  46. Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics. Cell. 1996;87:227–39.

    Article  CAS  PubMed  Google Scholar 

  47. Reinhard M, Giehl K, Abel K, Haffner C, Jarchau T, Hoppe V, et al. The proline-rich focal adhesion and microfilament protein VASP is a ligand for profilins. EMBO J. 1995;14:1583–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 1998;17:6932–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Vemuri B, Singh SS. Protein kinase C isozyme-specific phosphorylation of profilin. Cell Signal. 2001;13:433–9.

    Article  CAS  PubMed  Google Scholar 

  50. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65:5991–5.

    Article  CAS  PubMed  Google Scholar 

  51. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.

    Article  CAS  PubMed  Google Scholar 

  52. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12:488–96.

    Article  PubMed  Google Scholar 

  53. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.

    Article  PubMed  Google Scholar 

  54. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets. 2013;13:963–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.

    Article  PubMed  Google Scholar 

  56. Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol Res Pract. 2015;211:557–69.

    Article  CAS  PubMed  Google Scholar 

  57. Pang L, Li Q, Wei C, Zou H, Li S, Cao W, et al. TGF-beta1/Smad signaling pathway regulates epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: in vitro and clinical analyses of cell lines and nomadic Kazakh patients from northwest Xinjiang, China. PLoS One. 2014;9:e112300.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Valenzuela-Iglesias A, Sharma VP, Beaty BT, Ding Z, Gutierrez-Millan LE, Roy P, et al. Profilin1 regulates invadopodium maturation in human breast cancer cells. Eur J Cell Biol. 2015;94:78–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Authors’ contributions

YL, FL and YZC conceived and designed the experiments. XBC, SMZ, XYX, and HWD performed the experiments. XBC, SMZ and CXL analyzed the data. LY, JMH, JFJ, HLW, and NL contributed to patient collection and clinical data interpretation. XBC and SMZ wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by Grants from the Major science and technology projects of Shihezi University (No. gxjs2014-zdgg06), the National Natural Science Foundation of China (No. 81160301, 81360358, 81460362, 81560399, 81260301), the Ministry of Science and Technology of China (2012AA02A503), the high-level talent project of Shihezi University (No. RCZX201533), and the jointly foundation for nurturing the outstanding young scientists of Shihezi University (No. 2013ZRKXYQ-YD19). Thanks for the anonymous reviewers and editor for their valuable comments and suggestions that helped improve the quality of our manuscript.

Competing interests

The authors declare that they have no competing interests.

Author information

Author notes

    Authors and Affiliations

    1. Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, 832002, China

      Xiao-bin Cui, Shu-mao Zhang, Hong-wei Dang, Chun-xia Liu, Liang-hai Wang, Lan Yang, Jian-ming Hu, Wei-hua Liang, Jin-fang Jiang, Yun-zhao Chen & Feng Li

    2. Department of Pathology, Beijing ChaoYang Hospital, Capital Medical University, Beijing, 100020, China

      Xiao-bin Cui & Feng Li

    3. Department of Gynecology, Zhengzhou First People’s Hospital, Zhengzhou, 450000, China

      Yue-xun Xu

    4. Department of Oncology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, 832002, China

      Na Li

    5. Department of CT and MRI, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, 832002, China

      Yong Li

    Authors
    1. Xiao-bin Cui
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Shu-mao Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yue-xun Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Hong-wei Dang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Chun-xia Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Liang-hai Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Lan Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Jian-ming Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Wei-hua Liang
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Jin-fang Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Na Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Yong Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Yun-zhao Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. Feng Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Yong Li, Yun-zhao Chen or Feng Li.

    Additional information

    Xiao-bin Cui and Shu-mao Zhang contributed equally to this work

    Additional file

    12967_2016_884_MOESM1_ESM.docx

    Additional file 1: Table S1. The high sensitivity, specificity and AUC values of PFN2 in ESCC, HGIN, and LGIN.

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and Permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Cui, Xb., Zhang, Sm., Xu, Yx. et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma. J Transl Med 14, 137 (2016). https://doi.org/10.1186/s12967-016-0884-y

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12967-016-0884-y

    Keywords

    • Profilin 2
    • ESCC
    • Precursor lesions
    • Prognosis
    • Metastasis

    Journal of Translational Medicine

    ISSN: 1479-5876

    Contact us